Differences in the contribution of the CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients

Diabetes Care

Volumn 31, Issue 8, 2008, Pages 1608-1610

  Kawasaki, Eiji ^a   Imagawa, Akihisa ^b   Makino, Hideichi ^c   Uga, Miho ^a   Abiru, Norio ^d   Hanafusa, Toshiaki ^b   Uchigata, Yasuko ^e   Eguchi, Katsumi ^e  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR4 ANTIGEN; MESSENGER RNA; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; CLASSIFICATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; JAPAN; ONSET AGE; RISK;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIGENS, CD; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 49649096449     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0280     Document Type: Article

References (9)

1. Kawasaki E, Matsuura N, Eguchi K: Type 1 in Japan. Diabetologia 49:828-836, 2006
2. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678, 2007
3. Vaidya B, Pearce S: The emerging role of the CTLA-4 gene in autoimmune endocri- nopathies. Eur J Endocrinol 150:619-626, 2004
4. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shi- mada A, Shimizu I, Maruyama T, Makino H: Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48: 294-300, 2005
5. Ikegami H, Awata T, Kawasaki E, Koba- yashi T, Maruyama T, Nakanishi K, Shi- mada A, Amemiya S, Kawabata Y, Kurihara S, Tanaka S, Kanazawa Y, Mo- chizuki M, Ogihara T: The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. J Clin Endocrinol Metab 91:1087-1092, 2006
6. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988, 1995
7. McCoy K, Camberis M, Gros GL: Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med 186:183-187, 1997
8. Abe T, Yamaguchi Y, Takino H, Fujita N, Yamauchi DM, Ozaki M, Yamakawa K, Sera Y, Sakamaki H, Uotani S, Kawasaki E, Awata T, Yamasaki H, Eguchi K: CTLA4 gene polymorphism contributes to the mode of onset of diabetes with antiglutamic acid decarboxylase antibody in Japanese patients: genetic analysis of diabetic patients with antiglutamic acid decarboxylase antibody. Diabet Med 18: 726-731, 2001
9. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ: A native soluble form of CTLA-4. Cell Immunol 201:144-153, 2000